Endocrinology

Top Story

Pioglitazone improves NASH, reduces fibrosis in type 2 diabetes

December 13, 2017

Pioglitazone effectively reduced nonalcoholic fatty liver disease activity score in patients with nonalcoholic steatohepatitis with and without type 2 diabetes, according to a recently published study. Pioglitazone also reduced liver fibrosis in patients with type 2 diabetes, but increased adipose tissue insulin sensitivity.

“These results suggest that pioglitazone may provide the same metabolic and histologic benefits to patients with NASH and prediabetes and to those with NASH and [type 2 diabetes],” Fernando Bril, MD, from the University of Florida, and colleagues wrote. “Greater improvements in resolution of NASH may suggest specific pioglitazone mechanisms in the [type 2 diabetes] population. While the effects on fibrosis appear to be similar in both groups, pioglitazone may contribute to halt the rapid progression observed in this group.”

In the Journals Plus

Depression not linked with glycemic control in adolescents with type 2 diabetes

December 13, 2017
Symptoms of depression were not associated with glycemic control in adolescents with type 2 diabetes, although depression was common, according to findings from a
In the Journals Plus

Once-daily glucocorticoid therapy improves immune, metabolic function in adrenal insufficiency

December 13, 2017
Patients with primary or secondary adrenal insufficiency assigned to once-daily hydrocortisone therapy for 24 weeks experienced fewer infections and improved metabolic…
In the Journals Plus

Low vitamin D level may increase risk for heart failure hospitalization

December 13, 2017
Adults with a low serum 25-hydroxyvitamin D concentration are more likely to be admitted to the hospital with heart failure and spend more days in the hospital compared…
In the Journals Plus

Meta-analysis: GLP-1 receptor agonists reduce CV risks in type 2 diabetes

December 13, 2017
Adults with type 2 diabetes are effectively treated with GLP-1 receptor agonists compared with placebo and experience significant decreases in cardiovascular mortality…
More Headlines »
CNE CME CPE

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Video
Meeting News

VIDEO: Novel protein plus cold exposure promising for preventing obesity

October 31, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

CME CE

Innovations in Insulin: New Opportunities to Individualize Therapy

Presented by the Annenberg Center for Health Sciences.
This activity is supported by an independent educational grant from Novo Nordisk Inc.
This activity is supported by an educational grant from Lilly.

Vivian A. Fonseca, MD, and Jonathan D. Leffert, MD, combine their expertise and discuss emerging concepts, treatment…
More »
Current Issues
View the Current Issue